Evidence map›Paper›PMID 29080069›Full record

Trial reportLung2018

5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects.

Brian J Day, Jie Huang, Briana Q Barkes, May Gillespie, Li Li, Lisa A Maier

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lung, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brian J DayDepartment of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO, USA.
Jie HuangDepartment of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO, USA.
Briana Q BarkesDepartment of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO, USA.
May GillespieDepartment of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO, USA.
Li LiDepartment of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO, USA.
Lisa A MaierDepartment of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO, USA. maierl@njhealth.org.ORCID 0000-0001-6872-1769

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Exposure in Epigenetic Regulation of Immune Response in CBDR01ES023826 · NIEHS · NATIONAL JEWISH HEALTH · PI MAIER, LISA A, YANG, IVANA V · 2015 to 2019
$2.3M
Targeting Oxidative Stress in Chronic Beryllium DiseaseR01ES017582 · NIEHS · NATIONAL JEWISH HEALTH · PI DAY, BRIAN J, MAIER, LISA A · 2009 to 2013
$1.7M
Role of Oxidatve Stress in Chronic Beryllium DiseaseR01ES012504 · NIEHS · NATIONAL JEWISH HEALTH · PI DAY, BRIAN J · 2003 to 2006
$1.1M
NHLBI NIH HHS R01 012504NIEHS NIH HHS R01 ES012504NIEHS NIH HHS R01 ES017582NIH HHS P01 ES11810NIH HHS R01 ES017582NIH HHS R01 ES023826NIH HHS UL1TR001082
6 · The paper itself

Abstract

introductionChronic beryllium disease (CBD) is characterized by accumulation of macrophages and beryllium-specific CD4

methodsSeventeen CBD patients were randomized 3:1 to receive 5-ASA 500-mg capsules or placebo four times daily for 6 weeks orally. Primary study endpoints included changes in beryllium lymphocyte proliferation (BeLPT). Secondary endpoints included changes in bronchoalveolar lavage (BAL) fluid, cells, serum, and blood cell glutathione (GSH) levels, BAL cell TNF-α levels, lung function, and quality of life measures.

results5-ASA decreased BAL cell BeLPT by 20% within the 5-ASA treatment group. No significant changes were observed in serum, PBMCs, BALF, or BAL cell GSH levels in either the 5-ASA or placebo treatment group. 5-ASA treatment decreased ex vivo Be-stimulated BAL cell TNF-α levels within the 5-ASA group and when compared to placebo. Significant improvements were noted in quality of life measurements with 5-ASA treatment.

conclusions5-ASA's ability to decrease BAL cell BeLPT and Be-stimulated BAL cell TNF-α levels suggests that 5-ASA may impact the beryllium-specific immune response in CBD. 5-ASA use in other non-infectious granulomatous lung diseases, such as sarcoidosis, may prove to be a useful alternative treatment to corticosteroids for those with mild to moderate disease.

Indexed as

AgedAnti-Inflammatory Agents, Non-SteroidalBerylliosisBronchoalveolar Lavage FluidCell ProliferationChronic DiseaseDouble-Blind MethodFemaleGlutathioneHumansImmunity, CellularLeukocytes, MononuclearLymphocytesMaleMesalamineMiddle AgedAnti-Inflammatory Agents, Non-SteroidalGlutathioneMesalamineTumor Necrosis Factor-alpha5-Aminosalicylic acidBerylliosisGranulomaLungQuality of lifeTherapeutic trial (or therapy)TNF-alpha

Identifiers

PMID29080069
PMCPMC13227909

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.